They are available in a variety of formulations, including capsules, tablets, liquids, and powders, allowing for individualization based on preferences
We don't settle for less
So a careful, individualized approach is necessary for a smooth and safe transition
In the context of exendin-4, the -phe1 substitution is known to reduce binding affinity, reduce GLP-1R endocytosis, accelerate GLP-1R recycling, enhance insulin release, and improve anti-hyperglycaemic efficacy, while exendin-asp3 shows opposing characteristics (Jones et al., 2018b)
Andrabi, University of Alabama School of Medicine, USA Reviewed by Hirac Gurden, Paris Diderot University, France
UK approval through the MHRA typically follows FDA approval by 6 to 12 months